Therapeutic Vaccine Trials Should Focus More On Patient Response – Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A paradigm shift is needed in the field of therapeutic cancer vaccine trials that would evaluate patient response rather than tumor response, according to an analysis of prostate cancer vaccine trials in the July 1 issue of Clinical Cancer Research.
You may also be interested in...
Provenge Panel's Uncertainty Was More Persuasive To FDA Than Its Vote
FDA found the uncertainty expressed by the advisory committee reviewing Dendreon’s Provenge to be a better guide for regulatory action than the panel’s numerical vote supporting approval, according to the FDA review documents for the first autologous cancer vaccine.
Provenge Panel's Uncertainty Was More Persuasive To FDA Than Its Vote
FDA found the uncertainty expressed by the advisory committee reviewing Dendreon’s Provenge to be a better guide for regulatory action than the panel’s numerical vote supporting approval, according to the FDA review documents for the first autologous cancer vaccine.
R&D IN BRIEF
Methylnaltrexone disappoints Wyeth; updates on cancer vaccines; More R&D news, in brief